Long non-coding RNAs in cholangiocarcinoma

Aude Merdrignac, Panagiotis Papoutsoglou, Cédric Coulouarn

► To cite this version:

Aude Merdrignac, Panagiotis Papoutsoglou, Cédric Coulouarn. Long non-coding RNAs in cholangiocarcinoma. *Hepatology*, 2021, 73 (3), pp.1213-1226. 10.1002/hep.31534 . hal-02931583

HAL Id: hal-02931583

<https://hal.science/hal-02931583>

Submitted on 24 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

DR. AUDE MERDRIGNAC (Orcid ID : 0000-0002-0284-4755)

DR. CEDRIC COULOUARN (Orcid ID : 0000-0002-5692-9586)

Article type : Review

Long non-coding RNAs in cholangiocarcinoma

Aude Merdrignac ¹, Panagiotis Papoutsoglou ¹ and Cédric Coulouarn ¹ *

Author affiliations

¹ Inserm, Univ Rennes, COSS (Chemistry, Oncogenesis Stress Signaling), UMR_S 1242, CHU Rennes, Centre de Lutte contre le Cancer Eugène Marquis, Rennes, France.

aude.merdrignac@chu-rennes.fr

panagiotis.papoutsoglou@inserm.fr

cedric.coulouarn@inserm.fr

Keywords: cholangiocarcinoma, liver cancer, long non coding RNA, biomarker, signaling pathway

Contact information

Cédric COULOUARN, corresponding author *

Inserm UMR_S 1242, "Chemistry, Oncogenesis, stress, Signaling" (COSS)

Centre de Lutte contre le Cancer Eugène Marquis,

Rue de la Bataille Flandres Dunkerque, Bat D, F-35042 Rennes, France.

Tel : +33 2 2323 3881

E-mail: cedric.coulouarn@inserm.fr

List of abbreviations

CCA, cholangiocarcinoma; ICC, intrahepatic cholangiocarcinoma; HCC, hepatocellular carcinoma; ncRNAs, non coding RNAs; RNA, ribonucleic acid; miRNAs, microRNAs; lncRNAs, long non coding RNAs; circRNAs, circular RNAs; PTEN, phosphatase and tensin homolog; PI3K, phosphoinositide 3-kinase; HULC, highly upregulated in liver cancer; H19, H19 imprinted maternally expressed transcript; MALAT1, metastasis associated lung adenocarcinoma transcript 1; ceRNA, competing endogenous RNA; BAP1, BRCA1 associated protein 1; NEAT1, nuclear paraspeckle assembly transcript 1; siRNA, small interfering RNA; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; PRC, polycomb repressive complex; H3K27, lysine 27 on histone 3; CDH1, E-cadherin; H3K27me3, trimethylation of H3K27; SNHG, small nucleolar RNA host gene; CDKN1A, cyclin dependent kinase inhibitor 1A; TLR4, toll like receptor 4; NF- κ B, nuclear factor kappa B; SPRY4-IT1, SPRY4 intronic transcript 1; KLF2, kruppel like factor 2; LATS2, large tumor suppressor kinase 2; PVT1, PVT1 oncogene; DANCR, differentiation antagonizing non-protein coding RNA; TWIST1, twist family bHLH transcription factor 1; EMT, epithelial to mesenchymal transition; MEG3, maternally expressed 3; BMI1, BMI1 proto-oncogene, polycomb ring finger; RNF2, ring finger protein 2; HOTAIR, HOX transcript antisense RNA; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; CCAT, colon cancer associated transcript; PCAT1, prostate cancer associated transcript 1; TP73-AS1, TP73 antisense RNA 1; LINC, long intergenic non-protein coding RNA; TUG1, taurine up-regulated 1; BCL-2, BCL2 apoptosis regulator; BAX, BCL2 associated X, apoptosis regulator; MAP, mitogen-activated protein; AFAP1-AS1, AFAP1 antisense RNA

1

MMP, matrix metalloproteinase; CCND1, cyclin D1; MYC, MYC proto-oncogene, bHLH transcription factor; MIAT, MIAT, myocardial infarction associated transcript; UCA1, urothelial cancer associated 1; GSK, glycogen synthase kinase; SOX2-OT, SOX2 overlapping transcript; EPIC1, epigenetically-induced lncRNA1; bHLH, basic helix-loop-helix; LOXL1-AS1, LOXL1 antisense RNA 1; ATP, adenosine triphosphate; ABCA1, ATP-binding cassette transporter; CRNDE, colorectal neoplasia differentially expressed; NNT-AS1, NNT antisense RNA 1; ZEB1-AS1, ZEB1 antisense RNA 1; ZEB1, zinc finger E-box binding homeobox 1; HEIH, hepatocellular carcinoma up-regulated EZH2-associated long non-coding RNA; HECT, homologous to the E6-AP carboxyl terminus; HCCA, hilar cholangiocarcinoma; CXCR, C-X-C motif chemokine receptors; RNAseq, RNA sequencing; TGF β , transforming growth factor beta; TLINC, TGF β -induced long noncoding RNA; LFAR1, liver fibrosis-associated lncRNA1; LMCD1-AS1, LMCD1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; COL6A3, collagen VI-alpha3 chain; NNT-AS1, NNT antisense RNA 1; ERK, extracellular-signal-regulated kinase; ECC, extrahepatic cholangiocarcinoma; TNM, tumor node metastasis; MIR22HG, MIR22 host gene; ASAP1-IT1, ASAP1 intronic transcript 1; SMO, smoothened, frizzled class receptor; GLI1, GLI family zinc finger 1; SNPs, single nucleotide polymorphisms; GAPLINC, gastric adenocarcinoma predictive long intergenic non-coding; CPS1-IT1, carbamoyl-phosphate synthetase 1 intronic transcript 1; KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; FLVCR1-AS1, FLVCR1 antisense RNA 1; FOXO3, forkhead box O protein 3; FU,

fluorouracil; Cdr1as, cerebellar degeneration-related protein 1 antisense RNA; Oct-2, octamer transcription factor-2.

Financial Support: This work was supported by Inserm, Université de Rennes 1, and ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Santé) dans le cadre du Plan cancer (Non-coding RNA in cancerology: fundamental to translational; [Grant C18007NS to CC]). CC is a member of the European Network for the Study of Cholangiocarcinoma (ENSCCA) and participates in the initiative COST Action EURO-CHOLANGIO-NET granted by the COST Association (CA18122).

Conflicts of Interest: The authors declare no conflict of interest.

Abstract: Cholangiocarcinoma (CCA) is the second primary hepatic malignancy after hepatocellular carcinoma. CCA is characterized by its aggressiveness and poor prognosis associated with limited therapeutic options. Thus, a better understanding of molecular pathogenesis of CCA together with the identification of robust biomarkers and therapeutic targets is still necessary to improve the management of patients with CCA. In this review, we discuss the role of long non coding RNAs (lncRNAs) in CCA onset and progression. lncRNAs represent a heterogeneous class of RNA molecules with various genomic location and organization acting at both transcriptional and post-transcriptional levels. Notably, we provide an overview of the functions of lncRNAs in epigenetic modulation and regulation of signaling pathways and cell behaviors leading to tumor progression (e.g. apoptosis, survival, epithelial to mesenchymal transition, migration, invasion, angiogenesis). Moreover, we depict the clinical relevance of lncRNAs as biomarkers and emerging therapeutic targets in CCA.

Introduction

Cholangiocarcinomas (CCA) include malignant tumors originating from the bile ducts and exhibiting cholangiocyte differentiation features. CCA are classified into three types according to the anatomical location: intrahepatic, perihilar and distal CCA (Figure 1) (1, 2). Intrahepatic CCA (ICC) represent the second primary hepatic malignancy after hepatocellular carcinoma (HCC). CCA are aggressive and poor prognosis neoplasms with a median survival of 24 months after the initial diagnosis. Despite the recent identification of molecular alterations involved in CCA pathogenesis, including in the stromal compartment, there is no established molecular targeted therapy that significantly increases patient survival yet (1-5). Surgical resection remains the only potential curative treatment when feasible and performed at early stage of the disease (1, 6). Thus, a better understanding of molecular pathogenesis of CCA together with the identification of robust biomarkers and therapeutic targets is still necessary to improve the management of patients with CCA.

Non coding RNAs (ncRNAs) belong to a heterogeneous class of RNA molecules involved in numerous biological and pathological processes, including carcinogenesis (7). Based on their size and structure, ncRNAs include microRNAs (miRNAs), long non coding RNAs (lncRNAs) and circular RNAs (circRNAs). In CCA, miRNAs have been largely studied. For example, miR-21 is a well-known oncogenic miRNA overexpressed in CCA and involved in response to chemotherapy by modulating gemcitabine-induced apoptosis (8, 9). Its overexpression in plasma makes it a potential circulating biomarker for CCA diagnosis and prognosis (10). The first lncRNAs implicated in liver carcinogenesis were described in HCC (e.g. HULC, H19, MALAT1) (11). As an example, MALAT1 was identified early on as a prognostic factor in lung cancer and then in liver, breast and colon cancers. Further studies suggested that MALAT1 plays a general role in cell proliferation (12). However, lncRNAs remain poorly investigated in CCA. lncRNAs are defined by a size greater than 200 nucleotides and the lack of a functional open reading frame. They are transcribed by RNA polymerase II and can be polyadenylated. Transcriptome analysis by deep sequencing demonstrated that the number of lncRNAs is greater than the one of mRNAs. Genomic organization of lncRNAs is complex and can be described according

to their relationship to protein-coding genes: intergenic, sense, antisense, intronic and bidirectional (13). LncRNAs have been involved in pluripotency, differentiation or proliferation although the function of most lncRNAs remains largely unknown. They show tissue specific expression and are tightly regulated at multiple levels, involving chromatin marks, independent promoters, regulation by transcription factors and alternative splicing. LncRNAs are located into the nucleus, the cytoplasm and could be also secreted, notably within extracellular vesicles (EVs). Based on their cellular location, lncRNAs have been shown to modulate gene expression, notably by acting as chromatin remodeling factors or by interacting with transcription factors (14). LncRNAs have been also reported to modulate post-transcriptional mRNA processing, protein function or localization, and intercellular signaling through EVs (15). In the cytoplasm, lncRNAs and circRNAs could interact directly with miRNAs acting as competing endogenous RNAs (ceRNAs) (Figure 2) (16, 17). This review highlights lncRNAs according to their role in CCA carcinogenesis (Table 1).

LncRNAs and epigenetic modulation

In the nucleus, lncRNAs could act at epigenetic level, mainly as scaffolding for chromatin or histone modifiers (Figure 3). BAP1, as a chromatin modulator, can involve interactions with several methylation and deacetylase components and result in modulating gene expression. LncRNA NEAT1, a downstream target of BAP1, is upregulated in CCA and HCC as well as in lung, esophageal, and colorectal cancers (18, 19). NEAT1 is involved in responses to therapy as well as in maintenance of proliferative, migratory and invasive capabilities of CCA cells (18). Exogenous silencing of NEAT1 reduces cell proliferation, migration, invasion and colony-forming abilities. EZH2 is the catalytic subunit of polycomb repressive complex (PRC) 2, a protein complex involved in methylating lysine 27 on histone H3 (H3K27). The effect of NEAT1 on modulating EZH2 further supports a role in tumor progression (20). EZH2 recruitment by NEAT1 and subsequent repression of E-cadherin (*CDH1* gene) promote CCA migration and invasion. Depletion of NEAT1 causes a reduction in EZH2 binding to *CDH1* promoter and increases *CDH1* transcription. Chromatin immunoprecipitation using an H3K27me3 antibody found decreased enrichment of H3K27me3 at *CDH1* promoter upon NEAT1 depletion. Taken together, these data suggest that EZH2 is recruited by NEAT1 to the promoter of *CDH1* and that together they repress *CDH1* expression. NEAT1 can also regulate gene expression through its involvement in paraspeckle nuclear body formation (21).

SNHG1 is another example of lncRNA upregulated in liver cancer (22). SNHG1 promotes CCA malignancy by interacting with EZH2 and repressing *CDKN1A* encoding P21 cell cycle inhibitor. Knockdown of SNHG1 lowers the binding of EZH2 as well as H3K27me3 levels at *CDKN1A* promoter, resulting in *CDKN1A* increased transcription and P21 protein levels, thus decreasing CCA growth through cell cycle inhibition (23). SNHG1, as a ceRNA for miR-140, enhances TLR4 expression and activated NF- κ B signaling, thereby regulating growth and tumorigenesis in CCA (24).

LncRNA SPRY4-IT1, up-regulated in CCA, exerts oncogenic properties partly through repressing tumor suppressors KLF2 and LATS2 by scaffolding EZH2 (25). SPRY4-IT1 also acts as a molecular sponge for miR-

101-3p, antagonizing its ability to repress EZH2 translation. LncRNAs PVT1 and DANCR promote cell proliferation and migration in CCA cell lines by binding with EZH2 and then by epigenetically repressing the expression of ANGPTL4 and FBP1, respectively (26, 27). In another study, DANCR is suggested to boost CCA cell proliferation, migration, invasion and angiogenesis. Mechanistically, DANCR interacts with miR-345-5p and prevents its binding to TWIST1 mRNA encoding a transcription factor crucial for epithelial to mesenchymal transition (EMT) (28).

In contrast, MEG3 is one of the lncRNAs which exhibit tumor suppressive activities. MEG3 expression is decreased in lung, liver, prostate, and gastric cancer, as well as in multiple myeloma, meningioma, and glioma (29). In CCA, MEG3 exerts its tumor suppressive effects partly by reversing EMT (30). MEG3 represses CCA malignant progression at the epigenetic level by negatively regulating BMI1 and RNF2 expression, two major components of PRC1 complex. MEG3 also exhibits tumor suppressive effects by inhibiting NFkB signaling pathway via miR-361-5p regulation (31).

LncRNAs and cancer-associated signaling pathways

LncRNAs contribute to several hallmarks of cancer in CCA (Figure 4A). The mechanisms of deregulation of different signaling pathways are detailed below and summarized in Figure 4B.

Apoptosis and survival

Most of lncRNAs described in CCA so far promotes cell proliferation and reduces cell apoptosis. Thus, knockdown of several lncRNAs upregulated in CCA, including HOTAIR, PANDAR, CCAT2, PCAT1, TP73-AS1 and LINC01061, increases the expression of the pro-apoptotic markers caspase-3 and caspase-9 (32-37). Silencing of PANDAR and TUG1 also restrains the expression of the anti-apoptotic BCL-2 and increase the expression of BAX in CCA cells (33, 38). However, the underlying molecular mechanisms involved remain to be discovered. LncRNA AFAP1-AS1 is upregulated in CCA (39, 40). AFAP1-AS1 silencing decreases cell migration and invasion notably by downregulating MMP2 and MMP9. AFAP1-AS1 silencing also suppresses cell proliferation by arresting cell cycle via decreases of the protein levels of cyclin D1 (CCND1) and c-Myc (MYC). Both tumor volume and tumor weight are significantly decreased in mice xenografted with AFAP1-AS1 knocked down CCA cells (39). MIAT is another example of oncogenic lncRNA that enhances CCA cell proliferation by releasing the negative regulation of miR-551b-3p towards CCND1 mRNA (41). LncRNA UCA1, up-regulated in CCA, affects cell apoptosis and cell cycle by activating AKT/GSK-3 β /CCND1 signaling pathway (42). PI3K/AKT pathway is also activated by MALAT1 and SOX2-OT to promote CCA cell proliferation and invasion (43-45).

LncRNAs could alter gene expression by modulating transcription factors. RNA immunoprecipitation experiments demonstrated that EPIC1, a lncRNA upregulated in CCA, directly targets MYC, a key transcription factor regulating the expression of a wide range of genes involved in cell growth, proliferation and survival (46). Accordingly, MYC targets, including cyclin A/D and CDK9, are downregulated following EPIC1 silencing. LncRNA LINC01296 also targets MYCN transcription factor (47). By inhibiting miR-5095, LINC01296

upregulates the expression of MYCN and promotes cell viability, migration and invasion in CCA cells. LncRNA SNHG6 harbors a pro-tumorigenic role in different cancers (48). Its expression is elevated in CCA and related to cell proliferation, migration and angiogenesis. SNHG6 potentiates the expression of E2F8 transcription factor, which is required for normal cell cycle progression from G1 to S phase. Specifically, SNHG6 acts as a ceRNA for miR-101-3p, which targets E2F8 mRNA for degradation. Thus, increased SNHG6 expression inhibits the miR-101-3p-mediated silencing of E2F8 in CCA (49). LncRNA LOXL1-AS1, upregulated in CCA, is associated with unfavorable prognosis. LOXL1-AS1 could facilitate cell proliferation, migration and invasion and attenuate cell apoptosis (50). LOXL1-AS1 acts by sponging miR-324-3p to elevate ATP-binding cassette transporter (ABCA1).

EMT, migration and invasion

Several ncRNAs have been shown to play a key role in migration, invasion and therefore in metastatic process in CCA, notably by regulating EMT. As described above, NEAT1 is one of the lncRNAs involved in the repression of E-cadherin to promote CCA cell migration and invasion (20). *In vitro*, the knockdown of numerous lncRNAs upregulated in CCA (e.g. HOTAIR, CRNDE, PANDAR, TUG1, CCAT1, CCAT2, SPRY4-IT1, UCA1, NNT-AS1) also reduces the expression of mesenchymal markers (Vimentin, N-cadherin) and increases the expression of CDH1 epithelial marker, resulting in EMT reversion (25, 32-34, 38, 42, 51-53). In contrast, MEG3 exhibits tumor suppressive effects and its knockdown increases the expression of mesenchymal markers (30).

The oncogenic effects of lncRNAs through EMT are frequently mediated by their function as ceRNAs (e.g. CCAT1, SPRY4-IT1, TUG1, KCNQ10T1, UCA1, NNT-AS1) (25, 53-57). As an example, the oncogenic effects of CCAT1, which expression is increased in poor prognosis ICC, are at least partly mediated through miR-152 sponging (53, 58). Indeed, miR-152 inhibitors rescue the cell migration and invasion capability of CCA cells after CCAT1 knockdown. In CCAT1 silenced cells, miR-152 inhibitors increase the expression of N-cadherin and Vimentin, but reduce the expression of E-cadherin. In addition, lncRNA ZEB1-AS1 promotes EMT in CCA cells by sponging miR-200a and subsequently enhancing the expression of its target ZEB1. Interestingly, ZEB1-AS1 reinforces proliferation and metastasis of CCA *in vivo* and its expression correlates with poor prognosis in patients (59). LncRNA HEIH is over-expressed in CCA. HEIH induces cell proliferation, migration and invasion *in vitro* and promotes tumor growth *in vivo*. At the molecular level, HEIH sequesters miR-98-5p away from its target mRNA, including the HECT domain E3 ubiquitin protein ligase 4 (60). LncRNA LINC01410 also promotes CCA cell proliferation and migration. LINC01410 is highly expressed in CCA tissues and cell lines. It up-regulates SMAD5 by sponging miR-124-3p, thereby promoting CCA progression (61).

LncRNA MALAT1 has a key role in multiple cancers and is upregulated in CCA. In hilar cholangiocarcinoma cells (HCCA), MALAT1 knockdown significantly suppresses proliferation, migration and invasion (62). Acting as a ceRNA, MALAT1 exerts its promotive functions by miR-204-dependent CXCR4 regulation. H19 and HULC were up-regulated after both short and long-term oxidative stress, implying their pivotal roles in inflammation promotion and CCA pathogenesis. H19 and HULC regulate cell migration and invasion by increasing pivotal

inflammation cytokine IL-6 and chemokine receptor CXCR4 through sponging let-7a/let-7b and miR-372/miR-373, respectively (63). Xu et al. confirmed in 2017 that H19 promotes cell migration and invasion. Knockdown of H19 decreases proliferation, increases apoptosis and reverses EMT in CCA cells (64).

Transforming Growth Factor beta (TGF β) pathway is tightly implicated in EMT and CCA progression (65, 66). TLINC is a lncRNA induced by TGF β and upregulated in ICC. Its long isoform is associated with a migratory phenotype and promotes an inflammatory microenvironment through upregulation of IL8 both *in vitro* and in resected human ICC (67). The liver-enriched lncRNA LFAR1 induces CCA cell proliferation, migration and invasion, by positively regulating components of the TGF β pathway, such as TGFB1, SMAD2 and SMAD4. These effects are accompanied by a concomitant reduction of E-cadherin and an up-regulation of Vimentin (68). LncRNA LMCD1-AS1, upregulated in CCA, is an E2F1 target. LMCD1-AS1 exerts oncogenic properties in CCA cells by sponging miR-345-5p to upregulate COL6A3 level (69). COL6A3 is a well-known oncogene in several tumors implicated in extracellular matrix remodeling notably through PI3k-AKT and TGF β /Smad signaling pathways. LncRNA NNT-AS1 upregulated expression is correlated with a poor prognosis in CCA (70). Knockdown of NNT-AS1 impairs CCA cell proliferation, migration and invasion, and tumor growth *in vivo*. NNT-AS1 acts as a ceRNA against several miRNAs: miR-142-5p targeting HMGA2, miR-485 targeting BCL9 implicated in Wnt/ β -catenin pathway and miR-203 targeting ZEB1 and IGF1R implicated in EMT, PI3K/AKT and ERK1/2 pathways (51, 54, 70).

PCAT1 is an oncogenic lncRNA upregulated in multiple cancers (71). In extrahepatic cholangiocarcinoma (ECC), PCAT1 regulates tumor progression via the Wnt/ β -catenin signaling pathway (37). PCAT1 acts as a ceRNA against miR-122, a well-known tumor suppressor miRNA in HCC (72). In ECC cells, PCAT1 depletion decreases β -catenin levels and increases GSK3 β levels. In ECC cells co-transfected with miR-122 inhibitors and PCAT1 siRNAs, protein levels of β -catenin were restored and colony formation increased (37). In contrast, lncRNA MIR22HG acts as a tumor suppressor via Wnt/ β -catenin signaling pathway (73). Its down-regulation is related to high TNM stage and poor prognosis in CCA patients. MIR22HG inhibits cell proliferation, migration and invasion in CCA by negatively regulating the expression of proteins involved in the Wnt/ β -catenin signaling pathway (e.g. β -catenin, CCND1 and MYC). The effect of MIR22HG overexpression on CCA progression could be partly rescued by activating the Wnt/ β -catenin signaling pathway (73). LncRNA ASAP1-IT1 is upregulated in CCA and involved in CCA progression. Knockdown of ASAP1-IT1 impedes cell proliferation, cell migration and EMT. ASAP1-IT1 activates hedgehog pathway through upregulating SMO and GLI1, two hedgehog-related proteins (74).

Angiogenesis

As previously mentioned, several lncRNAs have been associated with angiogenesis in CCA, including PVT1, DANCR and SNHG6. PVT1 localizes downstream of the MYC gene. It is upregulated in CCA and promotes cell proliferation and migration (27). Interestingly, gene ontology analysis following PVT1 knockdown indicates that the most markedly overrepresented biological processes were pathways involved in cell proliferation, apoptosis

and angiogenesis. However, the role of PVT1 in angiogenesis remains to be formally confirmed by functional tests in CCA, as it was demonstrated in gastric cancer (75). DANCER was reported to promote angiogenesis in several cancers. In ovarian cancer, DANCER promotes angiogenesis through regulation of miR-145/VEGF axis (76). In CCA, DANCER was shown to affect numerous cellular processes, including cell proliferation, migration, invasion, EMT and angiogenesis (28). However, the underlying molecular mechanisms linking DANCER to angiogenesis remain to be characterized. Lastly, it was proposed that SNHG6 promotes angiogenesis in CCA by sponging miR-101-3p and subsequent activation of E2F8 (49).

LncRNAs and genetic variation

Genetic variations and/or alterations such as single nucleotide polymorphisms (SNPs), mutations and gene fusions referring to coding regions are common events in human carcinogenesis. LncRNAs which are less conserved across species are even more prone to genetic variations. Fujimoto et al. provided a comprehensive whole-genome mutational analysis of 300 liver tumors, including CCA, combined CCA-HCC and a majority of HCC (77). The analysis revealed *NEAT1* and *MALAT1* to be prominently mutated among non-coding genes. The LncRNASNP is a database of SNPs in LncRNAs in human and mouse (78). HULC and MALAT1 SNPs were found to be implicated in HCC carcinogenesis (79). However, no LncRNA SNP has been reported so far in CCA carcinogenesis.

Clinical relevance of LncRNA expression

LncRNAs as biomarkers

Multiple studies focused on evaluating miRNA abundance in tissue, serum and bile as diagnostic biomarkers in CCA (80, 81). Some of them were also identified as promising prognostic biomarkers in serum (80-82) (Figure 5). To date, most of the LncRNAs are overexpressed in CCA cells and tissues and were identified as regulators of carcinogenesis (e.g. epigenetic deregulation, EMT, apoptosis). This overexpression is also frequently associated with a poor prognosis (H19, SOX2OT, CRNDE, HOTAIR, GAPLINC, ANRIL) (32, 43, 52, 64, 83, 84) and poor histologic features (CCAT1, UCA1, AFAP1-AS1, PANDAR, TUG1, SPRY4-IT1, TP73-AS1, LINC01296, CPS1-IT1, KCNQ1OT1, LOXL1-AS1, lnc-PKD2-2-3, NNT-AS1, SNHG3) (25, 33, 35, 39, 42, 47, 50, 54, 56, 85-89). Conversely, MEG3, LINC01714 and MIR22HG are downregulated in CCA tissues (30, 73, 90). MEG3 and LINC01714 decreased expression is correlated with poor survival. Some LncRNAs are not yet relevant for prognosis and only serve as potential diagnostic biomarkers (e.g. NEAT1, SNHG1, PVT1, PCAT1, EPIC1, TLINC, MALAT1, LMCD1-AS1, LINC01061, FLVCR1-AS1) (20, 23, 27, 36, 37, 46, 62, 67, 69, 91). However, one can assume that the ideal biomarkers are those obtained with non-invasive tests from body fluids, such as serum or plasma (Figure 5). In a recent meta-analysis, LncRNAs were found to be of high diagnostic value for HCC and their expression could potentially be used as auxiliary biomarkers in confirming HCC diagnosis (e.g. UCA1, MALAT1, SPRY4-IT1) (57). A recent study found circulating PCAT1, MALAT1 and CPS1-IT1 significantly increased in plasma samples of HCCA patients (92).

LncRNAs as therapeutic targets

The capability of lncRNAs to regulate key oncogenic processes makes them relevant targets for therapeutic research. Although, actual drugs are unable to directly target lncRNAs, promising strategies are in development to achieve transcriptional silencing or functional inhibition of oncogenic lncRNAs (14). *In vivo*, transcriptional silencing of lncRNAs can be achieved by antisense oligonucleotides (ASOs), siRNA-mediated knock-down and CRISPR technology (93). Another way to target oncogenic lncRNAs is by compromising their functional properties, through interfering with lncRNA-protein interactions. Designing RNA/DNA aptamers or small molecules aims to target RNA recognition motifs of RNA-binding proteins or to disorganize the secondary or tertiary structure of lncRNAs (94). The ability of lncRNAs to sponge miRNAs could be also exploited to sequester oncogenic miRNAs. This mechanism has been used experimentally with an artificial lncRNA to overcome sorafenib resistance in HCC (95). In the context of cancer, lncRNA-targeting approaches are still in the pre-clinical phase. Several pre-clinical models, such as genetically engineered mice, patient-derived xenografts, xenografted human cells, patient-derived tumor organoids and zebrafish models are currently used to manipulate the expression of lncRNAs in cancer. To date, there are not complete clinical trials involving therapeutic targeting of lncRNAs. However, two clinical trials involving miRNAs with promising preliminary results and one that makes use of lncRNA H19 promoter to specifically target bladder cancer are the pioneer trials for ncRNA therapeutics (96).

In CCA, few lncRNAs were found to influence current therapeutics. NEAT1 is a downstream target of BAP1, a frequently mutated chromatin modulator, and contributes to sensitivity to gemcitabine in CCA cells (18). Inhibition of NEAT1 restores cell response to gemcitabine and could be a potential sensitizer. Conversely, the sensitivity of cells to gemcitabine could be enhanced by LINC01714, a downregulated tumor suppressive lncRNA in CCA (90). lncRNA lnc-PKD2-2-3, upregulated in CCA tissues and associated to poor prognosis, increases cancer stem cell marker expression in CCA cell lines (87). lnc-PKD2-2-3 also increases drug resistance to 5-FU in CCA cell lines and enhances sphere formation efficiency indicating that it may promote the acquisition of CCA stemness features. Accordingly, lnc-PKD2-2-3 expression is correlated with cancer stem cells markers in CCA suggesting an application to target cancer stem cells and to reverse drug resistance.

New players in the field: circRNAs

In a previous study, we highlighted circular isoforms of TLINC, a TGF β induced lncRNA, in CCA tissues (67). CircRNAs are particular ncRNAs mostly greater than 200 nucleotides characterized by covalently closed loop structures with neither 5' to 3' polarity nor polyadenylated tail (97). This structure is formed by a back-splicing that ligates a downstream splice donor site reversely with an upstream splice acceptor site (98). This circular structure renders circRNAs particularly resistant to the action of RNases. Thus, circRNAs may represent interesting stable biomarkers in tissues or circulating in EVs such as exosomes detectable in serum (Figure 5) (98, 99).

Some circRNAs were already identified as potential molecular biomarkers in CCA e.g. circRNA Cdr1as, Hsa_circ_0001649 and Circ2174 (100-102). Hsa_circ_0001649 is aberrantly downregulated in CCA tissues and cells, and its downregulation is associated with tumor size and differentiation grade in CCA (102). Overexpressed circRNA Cdr1as may serve as a potential molecular biomarker to predict the aggressive tumor progression and worse prognosis for CCA patients (100). Circ2174, an intergenic circRNA increased in ICC, can act as a sponge to regulate the expression of miR-149 and thereby modulating Oct-2 and interleukin-16 signaling pathways in CCA (101).

Conclusions

CCA are aggressive neoplasms resulting from a complex multifactorial carcinogenesis process. LncRNAs are implicated in a large variety of functions in cancer development. Their potential interactions with DNA, RNA and protein result in regulation of gene expression at epigenetic, transcriptional and post-transcriptional levels. They act as regulators of key processes in cancer, including EMT, apoptosis, and proliferation. Thus, lncRNAs represent a promising class of biomarkers for CCA diagnosis and prognosis, as well as promising therapeutic targets.

References

Author names in bold designate shared co-first authorship.

1. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol* 2020.
2. **Louis C, Papoutsoglou P**, Coulouarn C. Molecular classification of cholangiocarcinoma. *Curr Opin Gastroenterol* 2020;36:57-62.
3. **Raggi C, Correnti M**, Sica A, Andersen JB, Cardinale V, Alvaro D, Chiorino G, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. *J Hepatol* 2017;66:102-115.
4. Sulpice L, Desille M, Turlin B, Fautrel A, Boudjema K, Clement B, Coulouarn C. Gene expression profiling of the tumor microenvironment in human intrahepatic cholangiocarcinoma. *Genom Data* 2016;7:229-232.
5. Sulpice L, Rayar M, Desille M, Turlin B, Fautrel A, Boucher E, Llamas-Gutierrez F, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. *Hepatology* 2013;58:1992-2000.
6. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology* 2013;145:1215-1229.

7. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet* 2011;12:861-874.
8. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. *Gastroenterology* 2006;130:2113-2129.
9. **Selaru FM, Olaru AV, Kan T**, David S, Cheng Y, Mori Y, Yang J, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. *Hepatology* 2009;49:1595-1601.
10. **Correa-Gallego C, Maddalo D, Doussot A**, Kemeny N, Kingham TP, Allen PJ, D'Angelica MI, et al. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. *PLoS One* 2016;11:e0163699.
11. Takahashi K, Yan I, Haga H, Patel T. Long noncoding RNA in liver diseases. *Hepatology* 2014;60:744-753.
12. Huarte M. The emerging role of lncRNAs in cancer. *Nat Med* 2015;21:1253-1261.
13. He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: Novel insights into hepatocellular carcinoma. *Cancer Lett* 2014;344:20-27.
14. Klingenberg M, Matsuda A, **Diederichs S, Patel T**. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. *J Hepatol* 2017;67:603-618.
15. Wang M, Zhou L, Yu F, Zhang Y, Li P, Wang K. The functional roles of exosomal long non-coding RNAs in cancer. *Cell Mol Life Sci* 2019;76:2059-2076.
16. Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. *Oncogene* 2018;37:555-565.
17. Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* 2011;146:353-358.
18. Parasramka M, Yan IK, Wang X, Nguyen P, Matsuda A, Maji S, Foye C, et al. BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma. *Mol Cancer* 2017;16:22.
19. Yu X, Li Z, Zheng H, Chan MT, Wu WK. NEAT1: A novel cancer-related long non-coding RNA. *Cell Prolif* 2017;50.
20. Zhang C, Li JY, Tian FZ, Zhao G, Hu H, Ma YF, Yang YL. Long Noncoding RNA NEAT1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells. *Oncol Res* 2018;26:879-888.
21. Clemson CM, Hutchinson JN, Sara SA, Ensminger AW, Fox AH, Chess A, Lawrence JB. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles. *Mol Cell* 2009;33:717-726.
22. Thin KZ, Tu JC, Raveendran S. Long non-coding SNHG1 in cancer. *Clin Chim Acta* 2019;494:38-47.

23. **Yu Y, Zhang M, Wang N, Li Q**, Yang J, Yan S, He X, et al. Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma. *Cell Death Dis* 2018;9:746.
24. **Li Z, Li X**, Du X, Zhang H, Wu Z, Ren K, Han X. The Interaction Between lncRNA SNHG1 and miR-140 in Regulating Growth and Tumorigenesis via the TLR4/NF-kappaB Pathway in Cholangiocarcinoma. *Oncol Res* 2019;27:663-672.
25. **Xu Y, Yao Y, Jiang X**, Zhong X, Wang Z, Li C, Kang P, et al. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. *J Exp Clin Cancer Res* 2018;37:81.
26. **Wang N, Zhang C, Wang W**, Liu J, Yu Y, Li Y, Zhang M, et al. Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma. *Cell Death Dis* 2019;10:585.
27. **Yu Y, Zhang M, Liu J**, Xu B, Yang J, Wang N, Yan S, et al. Long Non-coding RNA PVT1 Promotes Cell Proliferation and Migration by Silencing ANGPTL4 Expression in Cholangiocarcinoma. *Mol Ther Nucleic Acids* 2018;13:503-513.
28. Zhu CY, Fan CR, Zhang YL, Sun QX, Yan MJ, Wei W, Liu GF, et al. LncRNA DANCR affected cell growth, EMT and angiogenesis by sponging miR-345-5p through modulating Twist1 in cholangiocarcinoma. *Eur Rev Med Pharmacol Sci* 2020;24:2321-2334.
29. **He Y, Luo Y, Liang B**, Ye L, Lu G, He W. Potential applications of MEG3 in cancer diagnosis and prognosis. *Oncotarget* 2017;8:73282-73295.
30. **Li J, Jiang X**, Li C, Liu Y, Kang P, Zhong X, Cui Y. LncRNA-MEG3 inhibits cell proliferation and invasion by modulating Bmi1/RNF2 in cholangiocarcinoma. *J Cell Physiol* 2019;234:22947-22959.
31. Lu WX. Long non-coding RNA MEG3 represses cholangiocarcinoma by regulating miR-361-5p/TRAF3 axis. *Eur Rev Med Pharmacol Sci* 2019;23:7356-7368.
32. **Qin W, Kang P**, Xu Y, Leng K, Li Z, Huang L, Gao J, et al. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma. *Sci Rep* 2018;8:12176.
33. Xu Y, Jiang X, Cui Y. Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma. *Onco Targets Ther* 2017;10:2873-2883.
34. Xu Y, Yao Y, Qin W, Zhong X, Jiang X, Cui Y. Long non-coding RNA CCAT2 promotes cholangiocarcinoma cells migration and invasion by induction of epithelial-to-mesenchymal transition. *Biomed Pharmacother* 2018;99:121-127.
35. **Yao Y, Sun Y**, Jiang Y, Qu L, Xu Y. Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo. *Biomed Pharmacother* 2018;106:260-266.

36. Yu A, Zhao L, Kang Q, Chen K, Li J, Fu H, Liu J, et al. LncRNA LINC01061 sponges miR-612 to regulate the oncogenic role of SEMA4D in cholangiocarcinoma. *Biochem Biophys Res Commun* 2019;513:465-471.
37. **Zhang F, Wan M**, Xu Y, Li Z, Leng K, Kang P, Cui Y, et al. Long noncoding RNA PCAT1 regulates extrahepatic cholangiocarcinoma progression via the Wnt/beta-catenin-signaling pathway. *Biomed Pharmacother* 2017;94:55-62.
38. Xu Y, Leng K, Li Z, Zhang F, Zhong X, Kang P, Jiang X, et al. The prognostic potential and carcinogenesis of long non-coding RNA TUG1 in human cholangiocarcinoma. *Oncotarget* 2017;8:65823-65835.
39. **Lu X, Zhou C, Li R**, Deng Y, Zhao L, Zhai W. Long Noncoding RNA AFAP1-AS1 Promoted Tumor Growth and Invasion in Cholangiocarcinoma. *Cell Physiol Biochem* 2017;42:222-230.
40. **Shi X, Zhang H, Wang M**, Xu X, Zhao Y, He R, Zhang M, et al. LncRNA AFAP1-AS1 promotes growth and metastasis of cholangiocarcinoma cells. *Oncotarget* 2017;8:58394-58404.
41. Chang W, Wang Y, Li W, Geng Z. Long non-coding RNA myocardial infarction associated transcript promotes the proliferation of cholangiocarcinoma cells by targeting miR-551b-3p/CCND1 axis. *Clin Exp Pharmacol Physiol* 2020;47:1067-1075.
42. Xu Y, Yao Y, Leng K, Li Z, Qin W, Zhong X, Kang P, et al. Long non-coding RNA UCA1 indicates an unfavorable prognosis and promotes tumorigenesis via regulating AKT/GSK-3beta signaling pathway in cholangiocarcinoma. *Oncotarget* 2017;8:96203-96214.
43. **Li Z, Li J**, Ji D, Leng K, Xu Y, Huang L, Jiang X, et al. Overexpressed long noncoding RNA Sox2ot predicts poor prognosis for cholangiocarcinoma and promotes cell proliferation and invasion. *Gene* 2018;645:131-136.
44. Wang C, Mao ZP, Wang L, Wu GH, Zhang FH, Wang DY, Shi JL. Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway. *Neoplasma* 2017;64:725-731.
45. Wei CX, Wong H, Xu F, Liu Z, Ran L, Jiang RD. IRF4-induced upregulation of lncRNA SOX2-OT promotes cell proliferation and metastasis in cholangiocarcinoma by regulating SOX2 and PI3K/AKT signaling. *Eur Rev Med Pharmacol Sci* 2018;22:8169-8178.
46. **Li Y, Cai Q, Li W**, Feng F, Yang L. Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth. *Biochem Biophys Res Commun* 2018;504:654-659.
47. **Zhang D, Li H**, Xie J, Jiang D, Cao L, Yang X, Xue P, et al. Long noncoding RNA LINC01296 promotes tumor growth and progression by sponging miR-5095 in human cholangiocarcinoma. *Int J Oncol* 2018;52:1777-1786.
48. Zhang S, Qiu D, Xie X, Shen Y. Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis. *BMC Cancer* 2020;20:343.

49. **Wang H, Wang L, Tang L**, Luo J, Ji H, Zhang W, Zhou J, et al. Long noncoding RNA SNHG6 promotes proliferation and angiogenesis of cholangiocarcinoma cells through sponging miR-101-3p and activation of E2F8. *J Cancer* 2020;11:3002-3012.
50. Zhang B, Zhou M, Zou L, Miao J, Wang Y, Li Y, Lu S, et al. Long non-coding RNA LOXL1-AS1 acts as a ceRNA for miR-324-3p to contribute to cholangiocarcinoma progression via modulation of ATP-binding cassette transporter A1. *Biochem Biophys Res Commun* 2019;513:827-833.
51. **Gu Y, Li C**, Xiao L, Li J, Pei H, Xu D, Jiang Y, et al. High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition. *Am J Transl Res* 2019;11:5438-5456.
52. Xia XL, Xue D, Xiang TH, Xu HY, Song DK, Cheng PG, Wang JQ. Overexpression of long non-coding RNA CRNDE facilitates epithelial-mesenchymal transition and correlates with poor prognosis in intrahepatic cholangiocarcinoma. *Oncol Lett* 2018;15:4105-4112.
53. Zhang S, Xiao J, Chai Y, Du YY, Liu Z, Huang K, Zhou X, et al. LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152. *Dig Dis Sci* 2017;62:3050-3058.
54. Gu Y, Zhu Z, Pei H, Xu D, Jiang Y, Zhang L, Xiao L. Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203. *Aging (Albany NY)* 2020;12:2333-2346.
55. Li O, Yi W, Yang P, Guo C, Peng C. Long non-coding RNA UCA1 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells through targeting microRNA-122. *Exp Ther Med* 2019;18:25-32.
56. Sun H, Li Y, Kong H, Dai S, Qian H. Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis. *Arch Biochem Biophys* 2018;658:7-15.
57. **Zheng C, Hao H**, Chen L, Shao J. Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. *Clin Transl Oncol* 2017;19:961-968.
58. Liu Z, Chen Q, Hann SS. The functions and oncogenic roles of CCAT1 in human cancer. *Biomed Pharmacother* 2019;115:108943.
59. **Jiao M, Ning S, Chen J**, Chen L, Jiao M, Cui Z, Guo L, et al. Long noncoding RNA ZEB1AS1 predicts a poor prognosis and promotes cancer progression through the miR200a/ZEB1 signaling pathway in intrahepatic cholangiocarcinoma. *Int J Oncol* 2020;56:1455-1467.
60. **Wan T, Wang H**, Gou M, Si H, Wang Z, Yan H, Liu T, et al. LncRNA HEIH promotes cell proliferation, migration and invasion in cholangiocarcinoma by modulating miR-98-5p/HECTD4. *Biomed Pharmacother* 2020;125:109916.
61. Jiang T, Wang C, Zhu Y, Han H. LINC01410 promotes cell proliferation and migration of cholangiocarcinoma through modulating miR-124-3p/SMAD5 axis. *J Gene Med* 2020;22:e3162.

62. Tan X, Huang Z, Li X. Long Non-Coding RNA MALAT1 Interacts With miR-204 to Modulate Human Hilar Cholangiocarcinoma Proliferation, Migration, and Invasion by Targeting CXCR4. *J Cell Biochem* 2017;118:3643-3653.
63. **Wang WT, Ye H, Wei PP**, Han BW, He B, Chen ZH, Chen YQ. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. *J Hematol Oncol* 2016;9:117.
64. **Xu Y, Wang Z**, Jiang X, Cui Y. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition. *Biomed Pharmacother* 2017;92:17-23.
65. Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, et al. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. *Liver Int* 2019;39 Suppl 1:43-62.
66. **Papoutsoglou P, Louis C**, Coulouarn C. Transforming Growth Factor-Beta (TGFbeta) Signaling Pathway in Cholangiocarcinoma. *Cells* 2019;8.
67. Merdrignac A, Angenard G, Allain C, Petitjean K, Bergeat D, Bellaud P, Fautrel A, et al. A novel transforming growth factor beta-induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma. *Hepatol Commun* 2018;2:254-269.
68. Chen C, Li H, Wang X, Wang L, Zeng Q. Lnc-LFAR1 affects intrahepatic cholangiocarcinoma proliferation, invasion, and EMT by regulating the TGFbeta/Smad signaling pathway. *Int J Clin Exp Pathol* 2019;12:2455-2461.
69. Yu J, Zhang B, Zhang H, Qi Y, Wang Y, Wang W, Wang Y, et al. E2F1-induced upregulation of long non-coding RNA LMCD1-AS1 facilitates cholangiocarcinoma cell progression by regulating miR-345-5p/COL6A3 pathway. *Biochem Biophys Res Commun* 2019;512:150-155.
70. **Huang L, Jiang X**, Kang P, Wang Z, Leng K, Ji D, Xu Y, et al. Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma. *Cancer Manag Res* 2019;11:7739-7749.
71. Ghafouri-Fard S, Dashti S, Taheri M. PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target. *Exp Mol Pathol* 2020;114:104429.
72. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgerirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. *Oncogene* 2009;28:3526-3536.
73. Hu X, Tan Z, Yang Y, Yang P. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/beta-catenin signaling pathway. *J Gene Med* 2019;21:e3085.

74. **Guo L, Zhou Y**, Chen Y, Sun H, Wang Y, Qu Y. LncRNA ASAP1-IT1 positively modulates the development of cholangiocarcinoma via hedgehog signaling pathway. *Biomed Pharmacother* 2018;103:167-173.
75. **Zhao J, Du P, Cui P**, Qin Y, Hu C, Wu J, Zhou Z, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. *Oncogene* 2018;37:4094-4109.
76. Lin X, Yang F, Qi X, Li Q, Wang D, Yi T, Yin R, et al. LncRNA DANCER promotes tumor growth and angiogenesis in ovarian cancer through direct targeting of miR-145. *Mol Carcinog* 2019;58:2286-2296.
77. **Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M**, Shiraishi Y, Tanaka H, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. *Nat Genet* 2016;48:500-509.
78. **Gong J, Liu W**, Zhang J, Miao X, Guo AY. lncRNASNP: a database of SNPs in lncRNAs and their potential functions in human and mouse. *Nucleic Acids Res* 2015;43:D181-186.
79. **Liu Y, Pan S**, Liu L, Zhai X, Liu J, Wen J, Zhang Y, et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. *PLoS One* 2012;7:e35145.
80. **Zhou J, Liu Z**, Yang S, Li X. Identification of microRNAs as biomarkers for cholangiocarcinoma detection: A diagnostic meta-analysis. *Clin Res Hepatol Gastroenterol* 2017;41:156-162.
81. Salati M, Braconi C. Noncoding RNA in Cholangiocarcinoma. *Semin Liver Dis* 2019;39:13-25.
82. **Wang LJ, Zhang KL, Zhang N**, Ma XW, Yan SW, Cao DH, Shi SJ. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. *Oncotarget* 2015;6:18631-18640.
83. Angenard G, Merdrignac A, Louis C, Edeline J, Coulouarn C. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. *Dig Liver Dis* 2019;51:1337-1343.
84. Wang XP, Song J, Liu GT, Wang JJ, Guo HF. Upregulation of gastric adenocarcinoma predictive long intergenic non-coding RNA promotes progression and predicts poor prognosis in perihilar cholangiocarcinoma. *Oncol Lett* 2018;16:3964-3972.
85. **Jiang XM, Li ZL**, Li JL, Zheng WY, Li XH, Cui YF, Sun DJ. LncRNA CCAT1 as the unfavorable prognostic biomarker for cholangiocarcinoma. *Eur Rev Med Pharmacol Sci* 2017;21:1242-1247.
86. Ma SL, Li AJ, Hu ZY, Shang FS, Wu MC. Coexpression of the carbamoylphosphate synthase 1 gene and its long noncoding RNA correlates with poor prognosis of patients with intrahepatic cholangiocarcinoma. *Mol Med Rep* 2015;12:7915-7926.
87. Qiu G, Ma D, Li F, Sun D, Zeng Z. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma. *Int J Oncol* 2019;55:45-58.
88. **Tian D, Wei X**, Zhu H, Zhu L, Li T, Li W. LncRNA-SNHG3 is an independent prognostic biomarker of intrahepatic cholangiocarcinoma. *Int J Clin Exp Pathol* 2019;12:2706-2712.

89. **Zeng B, Ye H, Chen J**, Cheng D, Cai C, Chen G, Chen X, et al. LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis. *Oncotarget* 2017;8:113650-113661.
90. **Shen S, Wang J, Zheng B**, Tao Y, Li M, Wang Y, Ni X, et al. LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma. *Mol Ther Nucleic Acids* 2020;19:446-457.
91. Bao W, Cao F, Ni S, Yang J, Li H, Su Z, Zhao B. IncRNA FLVCR1-AS1 regulates cell proliferation, migration and invasion by sponging miR-485-5p in human cholangiocarcinoma. *Oncol Lett* 2019;18:2240-2247.
92. **Shi J, Li X**, Zhang F, Kong L, Zhang X, Cheng Y, Guan Q, et al. The Plasma LncRNA Acting as Fingerprint in Hilar Cholangiocarcinoma. *Cell Physiol Biochem* 2018;49:1694-1702.
93. **Arun G, Diermeier SD**, Spector DL. Therapeutic Targeting of Long Non-Coding RNAs in Cancer. *Trends Mol Med* 2018;24:257-277.
94. Bonetti A, Carninci P. From bench to bedside: The long journey of long non-coding RNAs. *Current Opinion in Systems Biology* 2017;3:119-124.
95. Tang S, Tan G, Jiang X, Han P, Zhai B, Dong X, Qiao H, et al. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. *Oncotarget* 2016;7:73257-73269.
96. Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. *Cell* 2019;179:1033-1055.
97. Pan X, Xiong K. PredcircRNA: computational classification of circular RNA from other long non-coding RNA using hybrid features. *Mol Biosyst* 2015;11:2219-2226.
98. Chen LL, Yang L. Regulation of circRNA biogenesis. *RNA Biol* 2015;12:381-388.
99. Louis C, Desoteux M, Coulouarn C. Exosomal circRNAs: new players in the field of cholangiocarcinoma. *Clin Sci (Lond)* 2019;133:2239-2244.
100. **Jiang XM, Li ZL**, Li JL, Xu Y, Leng KM, Cui YF, Sun DJ. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as. *Eur Rev Med Pharmacol Sci* 2018;22:365-371.
101. Moirangthem A, Wang X, Yan IK, Patel T. Network analyses-based identification of circular ribonucleic acid-related pathways in intrahepatic cholangiocarcinoma. *Tumour Biol* 2018;40:1010428318795761.
102. Xu Y, Yao Y, Zhong X, Leng K, Qin W, Qu L, Cui Y, et al. Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells. *Biochem Biophys Res Commun* 2018;496:455-461.

Figure legends

Figure 1: Classification of biliary tract malignancies according to their anatomical location. Cholangiocarcinoma (CCA) are broadly classified into three main entities based on their anatomical location: intrahepatic CCA (iCCA) that develop within the liver from the second-order bile ducts (BD) and proximal intrahepatic BD. Extrahepatic CCA include perihilar CCA (pCCA) arising from both left and right hepatic ducts, and distal CCA (dCCA) found further down the BD, closer to Vater's ampulla. Adapted from (2).

Figure 2: Molecular functions of nuclear (left panels) and cytoplasmic (right panels) lncRNAs.

Figure 3: lncRNAs involved in epigenetic regulation. **A:** Oncogenic lncRNAs (e.g. NEAT1) recruit EZH2 (one component of PRC2) involved in H3K27 trimethylation (H3K27me3). Subsequently, increased H3K27me3 levels at the promoter of genes result in decreased gene transcription. **B:** Tumor suppressor lncRNA MEG3 negatively regulates PRC1 components (BMI1 and RNF2). Subsequently, ubiquitination of H2A could be decreased and transcription of tumor suppressor gene could be restored. PRC: polycomb repressive complex. TF: transcription factor. RNA pol II: RNA polymerase II. H3K27: histone H3 lysine 27. H2A: histone 2A. ub: ubiquitination.

Figure 4: lncRNAs regulate CCA progression through multiple ways. **A:** Examples of lncRNAs affecting the hallmarks of cancer, during CCA development. **B:** Signaling pathways such as NF- κ B, TGF β , Ras/MEK/ERK, PI3K/Akt, Wnt and Hedgehog play crucial roles in CCA and they regulate or they are modulated by lncRNA. lncRNAs induced or repressed in CCA are indicated with red and green color, respectively.

Figure 5: Non coding RNAs as innovative biomarkers in CCA. Biological material is obtained either by minimally invasive (blood, bile) or by invasive techniques (biopsies or tumor tissue from surgical hepatic resection). Non coding RNA expression (miRNA, lncRNA or circRNA) could be relevant for diagnosis and/or prognosis in the management of patients with CCA.

Table 1: Role of lncRNAs in CCA carcinogenesis.

lncRNA	up/dn	mechanism of action	biological functions	related pathways	targets	biomarker	ref.
NEAT1	up	epigenetic, mutation	proliferation, migration, invasion, EMT, resistance to therapeutic		EZH2, E-cadherin	diagnostic	18-21
SNHG1	up	epigenetic, ceRNA	proliferation, invasion, cell cycle	TLR4 NF- κ B	EZH2, CDKN1A, miR-140	diagnostic	22-24
SPRY4-IT1	up	epigenetic, ceRNA	apoptosis, proliferation, migration, invasion, EMT		EZH2, KLF2, LATS2, miR-101-3p	diagnostic	25
PVT1	up	epigenetic	apoptosis, proliferation, migration		ANGPTL4	diagnostic	27
DANCR	up	epigenetic, ceRNA	proliferation, migration, invasion, angiogenesis, EMT		FBP1, EZH2, miR-345-5p, TWIST1	diagnostic	26,28
MEG3	down	ceRNA, epigenetic	proliferation, migration, invasion, EMT	NF κ B	miR-361-5p, TRAF3, PRC1	diagnostic, prognostic	29-31
HOTAIR	up		apoptosis, migration, invasion, EMT			diagnostic, prognostic	32
PANDAR	up		apoptosis, proliferation, migration, invasion, EMT			diagnostic, prognostic	33
CCAT2	up		apoptosis, migration, invasion, EMT			diagnostic	34
PCAT1	up	ceRNA	apoptosis, proliferation, migration, invasion	Wnt/ β -catenin	miR-122	diagnostic	37,71
TP73-AS1	up		apoptosis, migration, invasion, EMT			diagnostic	35
LINC01061	up	ceRNA	apoptosis, proliferation, migration		miR-612, SEMA4D	diagnostic	36
TUG1	up	ceRNA	apoptosis, proliferation, migration, invasion, EMT		miR-145, Sirt3, GDH	diagnostic, prognostic	38,89
AFAP1-AS1	up		proliferation, migration, invasion, cell cycle	MAPK		diagnostic, prognostic	39,40
MIAT	up	ceRNA	apoptosis, proliferation, cell cycle		miR-551b-3p, CCND1	diagnostic	41
UCA1	up	ceRNA	apoptosis, cell cycle, proliferation, migration, invasion, EMT	AKT GSK-3 β CCND1	miR-122	diagnostic, prognostic	42,55
MALAT1	up	mutation, ceRNA	proliferation, migration, invasion	CXCR4, PI3K/AKT	miR-204	diagnostic	44,62
SOX2-OT	up		proliferation, invasion	PI3K/AKT		diagnostic, prognostic	43,45
EPIC1	up	TF	apoptosis, proliferation		MYC, cyclin A/D, CDK9	diagnostic	46
LINC01296	up	ceRNA	cell viability, migration, invasion		MYC, miR-5095	diagnostic, prognostic	47
SNHG6	up	TF, ceRNA	proliferation, migration, angiogenesis		miR-101-3p, E2F8	diagnostic	48,49
LOXL1-	up	ceRNA	proliferation, migration,		miR-324-3p,	diagnostic,	50

AS1			invasion and apoptosis	ABCA1		prognostic	
CRNDE	up		proliferation, migration, invasion, EMT			diagnostic, prognostic	52
CCAT1	up	ceRNA	migration, invasion, EMT		miR-152	diagnostic, prognostic	53,58,85
NNT-AS1	up	ceRNA	proliferation, migration, invasion, EMT	Wnt/ β-catenin, PI3K/AKT, ERK1/2	miR-485, BCL9, miR-142-5p, HMG2, miR-203	diagnostic, prognostic	51,54,70
KCNQ1OT1	up	ceRNA	proliferation, migration, invasion, apoptosis, EMT		miR-140-5p, SOX4	diagnostic, prognostic	56
ZEB1-AS1	up	ceRNA	proliferation, EMT		miR-200a, ZEB1	diagnostic, prognostic	59
HEIH	up	ceRNA	proliferation, migration, invasion		miR-98-5p, HECTD4	diagnostic	60
LINC01410	up	ceRNA	proliferation, migration		miR-124-3p, SMAD5	diagnostic	
H19	up	ceRNA	proliferation, migration, invasion, EMT, apoptosis	CXCR4 IL6	let-7a, miR-372	diagnostic, prognostic	63,64
HULC	up	ceRNA	migration, invasion	CXCR4 IL6	let-7b, miR-373	diagnostic	63,79
TLINC/CASC15	up		migration	TGFβ		diagnostic	67
LFAR1	up		proliferation, migration, invasion, EMT	TGFβ	TGFβ1, SMAD2, SMAD4	diagnostic	68
LMCD1-AS1	up	ceRNA	proliferation, invasion, apoptosis		miR-345-5p, COL6A3	diagnostic	69
MIR22HG	down		proliferation, migration and invasion	Wnt/β-catenin		diagnostic, prognostic	73
ASAP1-IT1	up		proliferation, migration, EMT	Hedgehog	SMO, GLI1	diagnostic, prognostic	74
GAPLINC	up		proliferation, migration, invasion			diagnostic, prognostic	84
ANRIL	up					prognostic	83
CPS1-IT1	up		proliferation, apoptosis			diagnostic, prognostic	86
lnc-PDK2-2-3	up		sphere formation, resistance to therapeutic			diagnostic, prognostic	87
SNHG3	up					diagnostic, prognostic	88
LINC01714	down		proliferation, migration, invasion, resistance to therapeutic		FOXO3	diagnostic, prognostic	90
FLVCR1-AS1	up	ceRNA	proliferation, migration, invasion			diagnostic	91

nuclear lncRNAs

cytoplasmic lncRNAs

hep_31534_f2.eps

hep_31534_f3.eps

hep_31534_f4.eps

hep_31534_f5.eps